Plixorafenib

N/A

Report date: 2023/05/29 16:36:01
NME

Base Information

Drug NamePlixorafenib
Drug Alias NameFORE-8394PLX-8394FORE-8394
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase B-raf inhibitorsB-raf V600E inhibitors
TargetsSerine/threonine-protein kinase B-rafB-raf V600E
Therapy Area/IndicationsHigh-Grade GliomaSolid tumoursHistiocytosis +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSweden +[11] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesDaiichi Sankyo Co LtdPlexxikon Inc
China Registration ClassN/A

Develop Information

Active CompaniesFore Biotherapeutics IncNovellus Ltd
Inactive CompaniesN/A
Active IndicationsHigh-Grade GliomaSolid tumours
Inactive IndicationsHistiocytosisCarcinoma, Non-Small-Cell LungThyroid Neoplasms +[8] 

Other Information

ATC CodeN/A
Related LinksN/A